Do understand that firstly, I in no way shape or form want to see a miss on the primary end-point....I want the news to be that BETonMACE met the primary end-point.  

With that being said, it is merely my opinion that failing to meet the primary endpoint...that it would mean the PPS falling below a quarter.  Hopefully its something we will never find out....but if the news is in fact 'failed to meet'...then I could be wrong and the PPS might not fall that low....I don't have a crystal ball.

I will support my opinion with the fact that missing would mean adding another 2+ years to Apabetalone's possible runway to approval, as there are no Phase 3 trials designed at this point.  It would mean another 2+ years of trying to prove that 208 has a marketable indication....trying to prove but not assured of proving.  

But again, here's hoping the question remains forever moot (debatable or academic).  I like your analogy of a 'Treasure Hunt' if the end-point is met.  I was thinking of it in terms of how the market analysts and talking heads parse through every announcement made by The Federal Reserve Bank...and its chair, trying to discern what it might mean in terms of the next announcement on the overnight lending rate.  

My sleep schedule is a mess right now....